Plus Therapeutics

Plus Therapeutics

Yahoo Finance • 17 days ago

Plus Therapeutics Rebranded As Cerenome With Focus Shift To CNS Oncology; 'CNSY' New Trading Symbol

(RTTNews) - Plus Therapeutics Inc. (PSTV), a precision diagnostics company, announced on Friday a corporate rebranding as Cerenome Inc., effective from August 3, 2026. The company will begin trading on the Nasdaq Capital Market under the t... Full story

Yahoo Finance • 23 days ago

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

HOUSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing targeted therapeutics and diagnostics for central nervous system (“CNS”) cancers, toda... Full story

Yahoo Finance • 30 days ago

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a regional agreement with Medical Mutua... Full story

Yahoo Finance • last month

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

HOUSTON and LAKE FOREST, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”) and Genomic Testing Cooperative, LCA (“GTC”) today announced a collaboration to integrate GTC’s next-gene... Full story

Yahoo Finance • last month

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

HOUSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), today highlighted the recent update to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncolo... Full story

Yahoo Finance • 2 months ago

Plus Therapeutics wins Elevance Health coverage deal

[Cancer cells on human tissue. 3D illustration.] anusorn nakdee * Plus Therapeutics (PSTV [https://seekingalpha.com/symbol/PSTV]) shares rose in early premarket trading after its subsidiary CNSide Diagnostics announced an agreement with... Full story

Yahoo Finance • 2 months ago

Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

HOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with Elevance Heal... Full story

Yahoo Finance • 3 months ago

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs by 40% Presentation receives blue-ribbon recognition at the ISPOR Annual Meeting, the premier global gathering... Full story

Yahoo Finance • 3 months ago

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

Partnership to deliver a novel AI-native integrated CNS oncology platform Platform will unify and analyze Plus’ proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision neuro-oncology HOUSTON, May 19, 202... Full story

Yahoo Finance • 3 months ago

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

HOUSTON, Texas, May 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous sys... Full story

Yahoo Finance • 4 months ago

Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Plus Therapeutics Inc. Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in metastatic CNS cancers HOUSTON, April 28, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus... Full story

Yahoo Finance • 4 months ago

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (... Full story

Yahoo Finance • 4 months ago

Plus Therapeutics regains compliance with Nasdaq

* Plus Therapeutics (PSTV [https://seekingalpha.com/symbol/PSTV]) said that [https://seekingalpha.com/pr/20480501-plus-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement] it has received a Nasdaq notice that its co... Full story

Yahoo Finance • 4 months ago

Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (... Full story

Yahoo Finance • 4 months ago

D. Boral Capital Downgrades Plus Therapeutics (PSTV) to Hold

Plus Therapeutics, Inc. (NASDAQ:PSTV) is one of the 8 Most Oversold Penny Stocks to Buy Right Now. On March 31, 2026, D. Boral Capital downgraded Plus Therapeutics, Inc. (NASDAQ:PSTV) to Hold from Buy ahead of a 1-for-25 reverse stock sp... Full story

Yahoo Finance • 5 months ago

Plus Therapeutics Announces Reverse Stock Split

Plus Therapeutics Inc. HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nerv... Full story

Yahoo Finance • 6 months ago

Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancer... Full story

Yahoo Finance • 8 months ago

Plus Therapeutics Expands CNSide Assay Platform to State of California

HOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeut... Full story

Yahoo Finance • 8 months ago

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central ne... Full story

Yahoo Finance • 8 months ago

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Cohort 1 data from multiple dose ReSPECT-Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM demonstrated promising safety and effi... Full story